Cord Blood Transplants Eyed As Therapy for Some Diseases

By E.B. Solomont

Published August 05, 2005, issue of August 05, 2005.
  • Print
  • Share Share

In a medical development with potentially far-reaching effects, researchers have transplanted cord blood into newborns with a rare genetic disease, preserving their brain development and performing a life-saving treatment for babies with a fatal genetic disorder.

Scientists from Duke University Medical Center and the University of North Carolina at Chapel Hill, infused cord blood stem cells after high-dose chemotherapy into a group of newborns with Krabbé disease, a condition in which children are missing an enzyme necessary to generate myelin, which insulates nerve cells and allows the transmission of nerve impulse.

In a study published in May in The New England Journal of Medicine, researchers said Krabbé patients — who had not yet developed symptoms but were treated after blood tests confirmed a diagnosis — showed age-appropriate developmental skills.

The treatment, researchers said, could be a precursor to therapy for other patients with metabolic disorders, including Tay-Sachs, for which several patients have undergone this same experimental treatment with varying success.

“It really opens the doors in terms of understanding other lysosomal diseases, and many of them have an effect on a nervous system and are deteriorating, like Krabbé disease,” said Dr. Maria Escolar, the lead author of the study. “We are trying to see if we can change the natural history of the disease.”

Since the first unrelated cord blood transplant was done in 1993, cord blood — harvested from the placenta or afterbirth — has most commonly been used to treat patients with leukemia, metabolic and bone marrow failure diseases.

With evidence that Krabbé patients benefited from bone marrow transplants, and knowing the disease presents itself in infancy, researchers were hopeful that cord blood would positively affect the babies.

To receive a cord blood transplant, patients first undergo chemotherapy to destroy their immune system and bone marrow, said Dr. Joanne Kurtzberg, director of the Duke pediatric blood and marrow transplant program. Then, cord blood is transfused and finds its way to the marrow where it repopulates the marrow and begins producing healthy cells, she said.

The healthy cells, which contain the enzyme Krabbé patients lack, circulate throughout the body and to the brain, replacing the missing enzyme and enabling the production of myelin.

With hospital stays, isolation to prevent infection and other health precautions during the first (and sometimes second) year of life, cord blood transplants are “not a simple procedure,” said Kurtzberg.

But the results in Krabbé patients are paying off. At least one patient who received a cord-blood transplant is in third grade and functions like a completely normal child, Kurtzberg said. “If you test him genetically, he still has the gene for the disease, but if you look at him functionally, he has no symptoms of the disease,” she said.

So far, the Duke-UNC team has transplanted 15 Krabbé newborns with cord blood, and all are in various stages of development, though they are following a similar course. Kurtzberg has transplanted 37 patients — some older — as well.

Six Tay-Sachs patients — two of them newborns at the time — have received cord-blood transplants. This has resulted in cognitive — but not motor — improvement.

“Certainly the jury is still out” for Tay-Sachs patients, said Jayne Gershkowitz director of the National Tay-Sachs & Allied Diseases Association. “Certainly this is showing great interest on the part of parents to see how this particular treatment will fare over time.”






Find us on Facebook!
  • From kosher wine to Ecstasy, presenting some of our best bootlegs:
  • Sara Kramer is not the first New Yorker to feel the alluring pull of the West Coast — but she might be the first heading there with Turkish Urfa pepper and za’atar in her suitcase.
  • About 1 in 40 American Jews will get pancreatic cancer (Ruth Bader Ginsberg is one of the few survivors).
  • At which grade level should classroom discussions include topics like the death of civilians kidnapping of young Israelis and sirens warning of incoming rockets?
  • Wanted: Met Council CEO.
  • “Look, on the one hand, I understand him,” says Rivka Ben-Pazi, a niece of Elchanan Hameiri, the boy that Henk Zanoli saved. “He had a family tragedy.” But on the other hand, she said, “I think he was wrong.” What do you think?
  • How about a side of Hitler with your spaghetti?
  • Why "Be fruitful and multiply" isn't as simple as it seems:
  • William Schabas may be the least of Israel's problems.
  • You've heard of the #IceBucketChallenge, but Forward publisher Sam Norich has something better: a #SoupBucketChallenge (complete with matzo balls!) Jon Stewart, Sarah Silverman & David Remnick, you have 24 hours!
  • Did Hamas just take credit for kidnapping the three Israeli teens?
  • "We know what it means to be in the headlines. We know what it feels like when the world sits idly by and watches the news from the luxury of their living room couches. We know the pain of silence. We know the agony of inaction."
  • When YA romance becomes "Hasidsploitation":
  • "I am wrapping up the summer with a beach vacation with my non-Jewish in-laws. They’re good people and real leftists who try to live the values they preach. This was a quality I admired, until the latest war in Gaza. Now they are adamant that American Jews need to take more responsibility for the deaths in Gaza. They are educated people who understand the political complexity, but I don’t think they get the emotional complexity of being an American Jew who is capable of criticizing Israel but still feels a deep connection to it. How can I get this across to them?"
  • “'I made a new friend,' my son told his grandfather later that day. 'I don’t know her name, but she was very nice. We met on the bus.' Welcome to Israel."
  • from-cache

Would you like to receive updates about new stories?




















We will not share your e-mail address or other personal information.

Already subscribed? Manage your subscription.